A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
This phase I clinical trial studies the side effects and best dose of trametinib in treating
patients with cancer that has spread to other places in the body and usually cannot be cured
or controlled with treatment (advanced) with or without liver (hepatic) dysfunction.
Trametinib may stop the growth of tumour cells by blocking proteins needed for cell growth.
When these proteins are blocked, the growth of cancer cells may be stopped and the cancer
cells will then die. Hepatic dysfunction is frequently found in patients with advanced
cancer and usually prevents patients from receiving standard treatments or from
participating in clinical trials. Patients may also need dose adjustments or absorb drugs
differently. Trametinib may be a better treatment for patients with advanced cancers and
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society